Key facts
- It has raised $1.1M; the latest was Accelerator/Incubator in Jun 2025.
- Notable investors include Creative Destruction Lab, MedTech Innovator, Front Row Ventures, Adara Venture Capital, CELS Valley Ready — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for BioMimir
- ·The full record, as it builds
Funding rounds
No funding rounds for BioMimir are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioMimir
Operator of a regenerative medicine company intended to design and manufacture synthetic biomimetic polymers that decrease inflammation. The company designs, develops, and commercializes biomaterial systems that are biodegradable and non-toxic hydrogels whose elastic properties are tuneable, enabling hospitals to provide patients with medicines for specific wounds and tissue repair.
- Sector
- Healthcare
- HQ
- Sherbrooke, Canada
- Founded
- 2021
- Employees
- 7
- Website
- biomimir.ca/
- Ownership
- Privately Held (backing)
BioMimir doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioMimir shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioMimir in its N-PORT filings yet. We sweep new filings monthly.